tbuckley/cabot-search huggingface dataset:
A multicenter, open-label phase II trial of second-line apatinib plus irinotecan in patients with advanced gastric cancer.
Authors: Jianjun Peng, Yong Li, Jianjun Xiao, Huaqiang Liu
Journal: Journal of Clinical Oncology (2022)

287 Background: The best choice of second-line chemotherapy regimen for patients with advanced gastric cancer is still debated. Anti-VEGF target therapy is proven to be effective both in second and third line settings. Apatinib, a highly selective VEGFR2 inhibitor, has been demonstrated to be efficacious and well-tolerated for third line of treatment in gastric cancer. The aim of this study is to evaluate the safety and efficacy of apatinib in combination with irinotecan in the second line treatment of advanced gastric cancer. Methods: With the expectation of improving PFS to 4.4m, this investigator-initiated, single arm, multi-center, registered phase II prospective study was designed to enroll 62 eligible patients diagnosed with advanced gastric cancer. Each participant was expected to receive chemotherapy plus apatinib (irinotecan 1800mg/m2, d1, Q2W; apatinib 500mg po qd). The severity of side effects was established according to Common Terminology Criteria for Adverse Events (CTCAE),Version 4.0. Efficacy assessed every three cycles (6 weeks) during the study. The primary endpoint was PFS. The secondary endpoint was OS, ORR, and DCR. The tumor response was determined according to RECIST 1.1 criteria. Results: Baseline characteristics (FAS population): From March 2019 to April 2021, 31 patients from 4 centers in Guangdong province were enrolled. Among them, 28 are eligible for analysis. There are 16 females and 15 males, median age 55 years old. Safety: 82.4% patients reported adverse events (AEs). The incidence of grade 3-4 AEs was 52.9%. Main 3-4 AEs were neutropenia (32.4%), leucopenia (17.6%), anorexia (8.8%), hypoalbuminaemia (8.8%), thrombocytopenia (5.9%), nausea (5.9%). Efficacy: By Aug 31th, 2021, 28 patients were evaluable for response and survival, 1 of them achieved complete response (CR), 10 of them achieved partial response (PR), 8 achieved stable disease (SD), and 9 experienced progression disease (PD). The ORR is 35.48%, the DCR is 61.29%. Median PFS is 4.40m, median OS is 6.64m. Conclusions: Adding apatinib to irinotecan chemotherapy as the second line treatment would be well tolerant in patients with advanced gastric cancer. This indicated the combination could be a potential treatment option for patients with advanced gastric cancer. Clinical trial information: ChiCTR1900021377.
Contents
Authors: Sandeep Ravindran, David Parke, Nathaniel Moxon, Anju Goyal, Joann Giaconi, Jamie Rosenberg, Emily Graubart, Evan Waxman, Daniel Knoch, Susan Forster, Privthi Sankar, Rukhsana Mirza, Andrew Duong, Sarah Van Tassel, Ana Alzaga Fernandez, Abha Amin, Nisha Chadha, Lora Dagi Glass, Inci Dersu, Zachary Elkin, Lisa Kelly, Pavlina Kemp, Meredith Regina, Pearl Rosenbaum, Prithvi Sankar, Grace Sun, Matthew Starr, Sanjay Patel, George Bartley, Erick Bothun, Maria Woodward, Jennifer Waljee, Pei-Chang Wu, Chueh-Tan Chen, Li-Chun Chang, Yu-Zhen Niu, Min-Li Chen, Li-Ling Liao, Kathryn Rose, Ian Morgan, Karla Zadnik, Jack Kane, Benjamin Connell, Yong Kim, Jin-Soo Kim, Sang Lee, Ahnul Ha, Jinho Lee, Young Park, Young Kim, Jin Jeoung, Ki Park, Ted Spaide, Yue Wu, Ryan Yanagihara, Shu Feng, Omar Ghabra, Jonathan Yi, Philip Chen, Francy Moses, Aaron Lee, Joanne Wen, Daniel Joseph, Edwin Ryan, Claire Ryan, Nora Forbes, Sushant Wagley, Yoshihiro Yonekawa, Robert Mittra, D Wilkin Parke, Geoffrey Emerson, Gaurav Shah, Kevin Blinder, Antonio Capone, George Williams, Omesh Gupta, Jason Hsu, Carl Regillo, Tiarnán Keenan, B Bch, Elvira Agrón, Julie Mares, Traci Clemons, Freekje Van Asten, Anand Swaroop, Emily Chew, Maximilian Wintergerst, Divyansh Mishra, Laura Hartmann, Payal Shah, Vinaya Konana, Pradeep Sagar, Moritz Berger, Kaushik Murali, Frank Holz, Mahesh Shanmugam, Robert Finger, Tjebo Heeren, Marcus Fruttiger, Konstantinos Balaskas, Roy Schwartz, Catherine Egan, Peter Charbel Issa, Lucia Sobrin, Yinxi Yu, Gayatri Susarla, Weilin Chan, Tian Xia, John Kempen, Rebecca Hubbard, Brian Vanderbeek, Adrian Fung, Sebastian Waldstein, Orly Gal-Or, Marco Pellegrini, Chiara Preziosa, Jerry Shields, R Welch, Rosa Dolz-Marco, David Sarraf, Aaron Nagiel, Robert Lalane, Jesse Jung, Nicola Ghazi, Prithvi Ramtohul, Jennifer Arnold, Yoichi Sakurada, Netan Choudhry, Chandrakumar Balaratnasingam, K Freund, Carol Shields, Aneesha Ahluwalia, Paula Feng, Hao Feng, Jessica Chow, Ravi Pandit, Turner Wibbelsman, Sean Considine, Thomas Jenkins, David Xu, Hannah Levin, Anthony Obeid, Allen Ho, David Plager, Sharon Freedman, M Wilson, Scott Lambert, Azin Abazari, Patrick Sibony, Jasmine Francis, Korey Jaben, Bianca Santomasso, Julia Canestraro, David Abramson, Paul Chapman, Meghan Berkenstock, Mary Aronow
Journal: Ophthalmology (2020)
IVUS guided PCI Anne L. Gaster, Per Thayssen, Knud E. Pedersen, Torben H. Haghfelt, Poul F. H�ilund-Carlsen, Lars Korsholm, Allan H. D. Johansen. Dept. of Cardiology. Odense University Hospital, Odense, Denmark
Journal: Journal of the American College of Cardiology (2001)
Vasovagal Syncope
Authors: David Moloney, Roman Romero-Ortuno, Rose Anne Kenny
Journal: JAMA Internal Medicine (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Integration of molecular cancer classification and NGS to identify metastatic patients eligible for IDH inhibitors.
Authors: Pashtoon Murtaza Kasi, Li Ma, Kai Treuner, Jenna Wong, Catherine A. Schnabel
Journal: Journal of Clinical Oncology (2022)

647 Background: Mutations in isocitrate dehydrogenase 1 and 2 ( IDH1 and IDH2) often occur in hematologic malignancies and solid tumors. Ivosidenib was recently approved for IDH1-mutated cholangiocarcinoma based on improved progression-free survival (PFS) and overall survival (OS). Notably, cancers of uncertain diagnoses presenting as liver metastases are often cholangiocarcinoma. While several trials are ongoing to evaluate IDH1/2 inhibitor efficacy in other advanced solid tumor types, currently eligibility for IDH inhibitor therapy requires both tumor type identification and IDH mutation confirmation. The 92-gene assay (CancerTYPE ID) is a gene expression classifier of 50 tumor types and subtypes for metastatic patients with diagnostic ambiguity. Multimodal biomarker testing, including next-generation sequencing (NGS), enables identification of actionable biomarkers to guide targeted therapy selection. Here, a database of metastatic cases that integrates tumor type with biomarker analysis was used to identify those eligible for IDH inhibitor treatment. Methods: MOSAIC (Molecular Synergy to Advance Individualized Cancer Care) is an IRB-approved, de-identified database of cases submitted for CancerTYPE ID testing with tumor type-guided multimodal biomarker testing by NGS (Neogenomics). In this study, metastatic cancers classified as pancreaticobiliary and other solid tumor types with IDH1/2 mutations were identified. Results: CancerTYPE ID determined 27 different tumor types in 2377 of 2572 cases (92.4%). The most common tumor type identified was pancreaticobiliary with 644 cases; subtypes with IDH1/2 mutation status are shown in the table. An IDH1 mutation was identified in 23 out of 78 (29.5%) cholangiocarcinoma cases which are eligible for ivosidenib treatment. IDH1/2 mutations were also detected in 11 other tumor types. For patients with IDH1 mutations, 28.2% were identified in tumor types with no FDA-approved IDH therapy, whereas 50.0% of IDH2 mutations overlapped with tumor types that have ongoing trials to determine the clinical benefit of targeting IDH2. Conclusions: These findings support the clinical utility of molecular tumor type classification combined with biomarker profiling to identify approved or investigational treatment options. The MOSAIC analysis identified metastatic patients with actionable aberrations ( IDH1) eligible for FDA-approved therapy, as well as those who may be eligible for investigational IDH inhibitor therapies based on tumor type and IDH1/2 mutation status. As new and approved IDH inhibitors are evaluated for efficacy, increased patient selection may be afforded through this approach in additional tumor types.[Table: see text]
<i>COVID-19 Stats:</i> COVID-19 Incidence,* by Age Group† — United States, March 1–November 14, 2020§
Authors: Likang Xu, Sandy Price, Catherine Mclean
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

44 yrs 45-79 yrs ≥80 yrs Abbreviation: COVID-19 = coronavirus disease 2019.* Incidence = cases per 100,000 calculated using 2019 U.S. Census population.† Age data for COVID-19 cases are based on case report forms submitted by state and territorial jurisdictions for confirmed and probable cases.Reporting for some jurisdictions is incomplete.Age is missing for 1% of case reports.§ Data are provisional and subject to change.During late March-late May, COVID-19 incidence was highest among adults aged ≥80 years, with a peak in incidence in the week beginning April 12.In June, incidence increased in all age groups, with the most rapid rate of increase and highest overall incidence among young adults aged 18-24 years; the rate in this group continues to be the highest among all age groups.Incidence steadily increased among children and adolescents (aged 0-17 years).The incidence in high school-aged persons (aged 14-17 years) was markedly higher than that in younger children by early July, then decreased before increasing in September.During late September-early October, weekly incidence decreased among young adults aged 18-24 years only, then continued to steadily increase among all age groups through November 14.
ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography
Authors: Daniel B. Mark, Daniel S. Berman, Matthew J. Budoff, J. Jeffrey Carr, Thomas C. Gerber, Harvey S. Hecht, Mark A. Hlatky, John McB. Hodgson, Michael S. Lauer, Julie M. Miller, Richard L. Morin, Debabrata Mukherjee, Michael Poon, Geoffrey D. Rubin, Robert S. Schwartz
Journal: Journal of the American College of Cardiology (2010)
International Cancer Research Technology Transfer Programme, 1978
Journal: JNCI Journal of the National Cancer Institute (1978)

International Cancer Research Technology Transfer Programme, 1978 JNCI: Journal of the National Cancer Institute, Volume 60, Issue 5, May 1978, Page 1183, https://doi.org/10.1093/jnci/60.5.1183-c Published: 01 May 1978
The importance of biopsy procedures
Authors: G. E. Moore
Journal: JAMA (1968)

Biopsy procedures of all kinds should be used far more frequently, not only for establishing initial diagnoses but also for providing more accurate clinical surveillance of the disease process. Frozen section and other techniques for rapid processing should be adopted in order to supply the clinician with more current pathological information. In the future, it is hoped that all biopsy reports can be made available within a few hours after the procedure itself.
The Operative Treatment of Strabismus.
Authors: George M. Gould
Journal: JAMA (1902)

An answer to Dr. Geo. M. Gould's paper in The Journal of the American Medical Association, November 1, page 1106. Pittsburg, Pa., Dec. 3, 1902. <h3>To the Editor:</h3> —If in the following I shall attempt to refute some of Dr. Gould's arguments against the operative treatment of heterophoria and strabismus, I am fully aware of the difficulty of the task. With his overwhelming figures, the weight of his well-earned reputation, and the admirable spirit of sincerity which pervades every phase of his reasoning, Dr. Gould's position is formidable enough to intimidate any "deus minoris gentis." However, I believe that in the seemingly impregnable wall with which the gallant defender of conservatism has surrounded himself, there are several weak spots; some of the fundamental stones are loosened already by the able efforts of others, and here and there I even find that the builder has altogether neglected to support his foundation
Bio‐Conductive Polymers for Treating Myocardial Conductive Defects: Long‐Term Efficacy Study (Adv. Healthcare Mater. 2/2022)
Authors: Anne Fu, Yahan Yang, Jun Wu, Shu‐Hong Li, Yunfei Fan, Terrance M Yau, Ren‐Ke Li
Journal: Advanced Healthcare Materials (2022)

Conductive Biopolymers PAMB-G is a non-toxic, injectable conductive polymer; it has shown good biocompatibility, as well as long-term efficacy and stability in alleviating arrhythmia by improving conduction across the fibrotic scar tissue post-myocardial infarction. This improvement aids in restoring cardiac function and can be found in article number 2101838 by Ren-Ke Li and co-workers.
Virology
Authors: Robert F. Betts
Journal: JAMA (1989)

This text, which is also published as a section of<i>Microbiology</i>, fourth edition, by Davis, Dulbecco, Eisen, and Ginsberg, serves as much more than a handbook, but less than a reference text in virology aimed at the beginning student. It is a nice working together of eight introductory chapters on the nature of viruses and viral immunology followed by 15 chapters on specific viruses or virus groups. The book includes relatively up-to-date material on the oncogenic viruses, including human T-cell lymphotropic virus I and human immunodeficiency virus 1. The individual familiar with basic biochemistry but unfamiliar with an understanding of virology can glean a good understanding of basic virology from the introductory chapters. With these basic concepts, one then can approach each of the chapters on the virus groups to expand on this introductory material and to gain a greater understanding. The breadth of basic material provided is succinct but
From the Congressional Office of Technology Assessment
Authors: R. Y. Nishimi
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Профессор КАНИЩЕВ Павел Андреевич (1923–2013)
Authors: . .
Journal: GASTROENTEROLOGY (2013)

2 мая 2013 г. в возрасте 89 лет после продолжительной болезни скончался доктор медицинских наук, профессор Канищев Павел Андреевич.Павел Андреевич родился 29 мая 1923 года в г. Астрахани. После успешного окончания средней школы в 1940 г. поступил в Астраханский медицинский институт. В годы войны был в эвакуации и заканчивал учебу в г. Одессе. Уже в годы учебы проявлял интерес к науке, институт закончил с отличием. Владел английским, французским и немецким языками. В 1966 г. начал работать во вновь организованном Институте гастроэнтерологии в должности заведующего отделом заболеваний желудка и двенадцатиперстной кишки. В 1979 г. стал первым заведующим кафедрой последипломного образования Днепропетровского медицинского института и разработал систему переподготовки кадров для гастроэнтерологической службы страны.
Adjustment Notebook for Student Nurses
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
JAMA Reference Directories
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A NEW STRATEGY FOR DISCONTINUATION OF DUAL ANTIPLATELET THERAPY: REAL SAFETY AND EFFICACY OF 3 MONTHS DUAL ANTIPLATELET THERAPY FOLLOWING ENDEAVOR ZOTAROLIMUS-ELUTING STENT IMPLANTATION
Authors: Myeong-Ki Hong, Byeong-Keuk Kim, Dong-Ho Shin, Young-Guk Ko, Donghoon Choi, Jung-Han Yoon, Hyuck-Moon Kwon, Yangsoo Jang
Journal: Journal of the American College of Cardiology (2012)
Internal cardioversion of permanent atrial fibrillation in severe heart failure is effective and leads to long term functional improvement Gaetano De Ferrari, Maurizio Landolina, Francesco Cant�, Michela Casella, Barbara Petracci, Carlo Campana, Stefano Ghio, Luca Lanzarini. S.Matteo Hospital - IRCCS, Pavia, Italy
Journal: Journal of the American College of Cardiology (2001)
China Biotech Scene, U.S. Collaborations Grow
Journal: Cancer Discovery (2020)

Amgen recently made a $2.7 billion deal with the Chinese biotechnology company BeiGene in an effort expedite oncology drug development and expand its market into China. The deal also reflects a broader shift in drug development: There is increasing collaboration between U.S. and Chinese firms as China's biotech scene has rapidly expanded due to policy and regulatory changes.
The Hospitals of London
Authors: None Cormack, None Semple
Journal: BMJ (1851)

Lecturer on YateriaZAedica at, (Gug's Hospital.GENTLEM1EN,-TIhe subject of mortality in Hospitals, which has of late attractedl the notice of the profession, will inaturally occupy your attention.I am therefore anxious to bring before you a plan of return, which, were it generally adopted, would at once shew the fact of increased mortal'ity in any particular hospital or hospitals, with a degree of accuracy such as I am not aware has yet been attempted.I cannot refrain from expressing regret that, while careful analysis of statistical returns supplies us with most valuable knowledge, it is still, unfortunately, too evident that this analysis is, even in the present day, occasionally neglected ; and that returns, in themselves correct, are made instrumental-to fallacious reasoning, and the promulgation of the grossest errors.It will be well, perhaps, here to enumerate, in the first place, some of the causes for variation, which must affect hospital statistics, and invalidate returns referring to the total deaths per annum, in so far, at least, as they may be used in comnparing the mortality of one Hospital with another.
Table of Contents
Authors: C Kojima, D Ramirez, E Tokar, S Himeno, Z Drobná, M Stýblo, R Mason, M Waalkes, M Brydøy, J Oldenburg, O Klepp, R Bremnes, E Wist, T Wentzel-Larsen, E Hauge, O Dahl, S Fosså, M Hauptmann, P Stewart, J Lubin, L Beane, R Hornung, R Herrick, R Hoover, J Fraumeni, A Blair, R Hayes, K Wasilewski-Masker, Q Liu, Y Yasui, W Leisenring, L Meacham, S Hammond, A Meadows, L Robison, A Mertens, I Deltour, C Johansen, A Auvinen, M Feychting, L Klaeboe, J Schüz, M Kok, C Holm-Wigerup, R Michalides, O Stål, S Linn, G Landberg, S Howell, A Wardley, A Response, T Nielsen, M Cheang, S Chia, D Voduc, D Gao, S Leung, P Bernard, C Perou, M Ellis, M Risk, C Spitz, A Amos, Q D'amelio, C Dong, M Response, S Trials, J Zohar, C Response, J Le Tourneau, L Lee, C Oakman, E Moretti, C Sotiriou, G Viale, A Di, Leo Response, K Pritchard, F O'malley, L Shepherd, M Levine, D Tu, V Bramwell, I Andulis
Journal: JNCI Journal of the National Cancer Institute (2009)
Errors in Figure 3 and Supplement
Authors: Ashley Choi, Hui-Jie Lee, Matthew Hartwig
Journal: JAMA Cardiology (2020)

Yuanjie Pang, DPhil; Christiana Kartsonaki, DPhil; Jun Lv, PhD; Zammy Fairhurst-Hunter, DPhil; Iona Y. Millwood, DPhil; Canqing Yu, PhD; Yu Guo, MSc; Yiping Chen, DPhil; Zheng Bian, MSc; Ling Yang, PhD; Junshi Chen, MD; Robert Clarke, MD; Robin G. Walters, PhD; Michael V. Holmes, PhD; Liming Li, MD; Zhengming Chen, DPhil